No Data
Guangzhou LBP Medicine Science & Technology (688393.SH): did not participate in the research and development of the Ruijin Pathology large model.
On February 17, Glonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) announced that the company did not participate in the research and development of the Ruijin Pathology Large Model. In May 2022, the company signed a Memorandum of Understanding with Huawei Technologies Co., Ltd. for the "Hematology Pathology Diagnosis Contract Based on the Ascend AI Hardware Platform," with the cooperation intention including exploring native trustworthy AI and explainable AI technology in pathology imaging. As of the date of this announcement, the cooperation between both parties has not resulted in specific products. In August 2020, the company signed a Global Strategy cooperation agreement with Tencent Technology (Shenzhen) Co., Ltd., with the cooperation content being the application of AI technology in microscopic image analysis.
Guangzhou LBP Medicine Science & Technology (688393.SH): The "cytological reagents + slide staining equipment + scanner + AI interpretation" intelligent overall screening solution has been promoted and trialed in the Hospital pathology department.
On February 12, 2023, Guangzhou LBP Medicine Science & Technology (688393.SH) disclosed its investor relations activity record, showing that the company is collaborating with Tencent AI Lab to develop an AI-assisted cervical cytology system, with Guangzhou LBP providing data and expert support, and Tencent providing algorithm capabilities. The main issue this product addresses is the screening process, which has already completed clinical trials and is currently in the registration phase for Class III certification. There is a notable lack of pathologists in the country, and cytological diagnosis heavily relies on the interpretation by doctors. The anticipated scenario is that AI will complete most of the screening tasks, allowing doctors to focus their attention on suspicious areas.
Guangzhou LBP Medicine Science & Technology (688393.SH): Cooperation with Huawei focuses on comprehensive digital solutions for the pathology department.
On February 12, Glonghui reported that Guangzhou LBP Medicine Science & Technology (688393.SH) disclosed the record of investor relations activities, showing that the company's collaboration with Huawei focuses on a comprehensive digital solution for pathology, combining Huawei's storage and computing technology to address the issues of large data volume storage and efficient retrieval of pathological slides, ensuring diagnostic efficiency. In terms of technological application, it mainly constructs a pathology database through generative AI to optimize Data Storage and retrieval; at the same time, it explores interpretable AI technology to achieve alignment of diagnostic information from pathological images with semantics, enhancing doctors' trust in AI results.
Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Surges 22%; Retail Investors Who Own 45% Shares Profited Along With Insiders
Guangzhou LBP Medicine Science & Technology Co., Ltd.'s (SHSE:688393) 29% Price Boost Is Out Of Tune With Earnings
Guangzhou LBP Medicine Science & Technology (688393.SH) and its subsidiaries have obtained multiple qualifications.
Guangzhou LBP Medicine Science & Technology (688393.SH) issued an announcement that the company and its subsidiaries will achieve domestic... in October to December 2024.
Risks Still Elevated At These Prices As Guangzhou LBP Medicine Science & Technology Co., Ltd. (SHSE:688393) Shares Dive 26%
